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This study used PET to measure the time course of the brain
concentration of 18F-labeled N-(4-acetyl-1-piperazinyl)-p-flu-
orobenzamide monohydrate (FK960), a novel antidementia
drug, after oral administration to conscious rhesus monkeys.
Methods: Three young-adult male rhesus monkeys were
tested. FK960 (0.1 mg/kg) containing about 370 MBq of 18F-
FK960 was administered orally to each monkey. Dynamic PET
images were acquired for 4 h from 5 min after the administra-
tion. Arterial blood samples were withdrawn during PET scan-
ning and were analyzed by an automatic well -counter and
thin-layer chromatography to determine the time course of au-
thentic 18F-FK960 activity concentration in plasma. FK960 con-
centrations in brain and plasma were calculated in units of mol/L
using the specific activity of FK960 preparations. Results: 18F-
FK960 penetrated the blood–brain barrier and underwent per-
fusion-dependent distribution in the entire brain. Maximal con-
centrations in the brain and plasma were 1.11  0.30  107
mol/L (at 3.0  0.6 h after administration) and 4.04  1.29 
107 mol/L (at 2.0  1.1 h after administration), respectively.
Conclusion: We succeeded in measuring the FK960 concen-
tration in the brains of conscious monkeys and in plasma after
oral administration at a dose of 0.1 mg/kg. The results sug-
gested that this method can measure the FK960 concentration
in the human brain, and a potential use of the PET technique in
drug development was demonstrated.
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To succeed in new drug development, dose setting in a
clinical trial is important. Because each drug has its corre-
sponding target site, achievement of the most suitable drug
concentration in the target organ or tissue becomes critical
to allow the drug to exhibit maximal effect. Although phar-
macokinetic data in animal experiments are usually used to
estimate the clinical dose, discrepancies in absorption, dis-
tribution, and metabolism of drugs between experimental
animals and humans still remains in most cases, and these
make the dose estimation difficult. Especially when a drug
acts in the brain, further difficulty is caused by the presence
of a defense system, the blood–brain barrier.
N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohy-
drate (FK960) (Fig. 1) is a novel potential antidementia drug
that has improved memory impairment in several kinds of
rodent and nonhuman primate animal models (1–3). How-
ever, the dose–response relationships of FK960 in memory
improvement in animal models of amnesia and in the en-
hancement of long-term potentiation (LTP) in hippocampal
slices were bell shaped (1,2). The dose–response relation-
ship of somatostatin in enhancement of LTP in hippocampal
slices was also bell shaped (4). Therefore, suitable dose
setting is still more critical for FK960 to exhibit efficacy in
patients.
Recently, we succeeded in synthesizing 18F-labeled
FK960 using an automated apparatus for 18F labeling to
serve in a PET study (5). Because PET can measure radio-
activity concentration dynamically in a target organ in a
living subject with minimal invasion, the acquisition of
bridging data between animals and humans may be ex-
pected. FK960 is also a drug to be administered perorally;
therefore, in the present study, we measured the brain con-
centration of FK960 after oral administration in conscious
monkeys using PET with 18F-FK960, which may reduce any
discrepancies in the obtained data between animals and
humans. A human PET study similar to the present study
will need to be performed with the subjects conscious.
MATERIALS AND METHODS
Animals
Studies were performed on 3 male rhesus monkeys (Macaca
mulatta; age, 7 y; body weight range, 8.08–9.08 kg). The monkeys
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were maintained and handled in accordance with the recommen-
dations of the United States National Institutes of Health, and all
animal experiments were performed in compliance with the animal
ethics committee of The Medical and Pharmacological Research
Center Foundation (Hakui, Japan). Each monkey had a specially
designed head holder (6,7), and this was used to stereotactically fix
each monkey’s head to a chair during PET scanning. The monkeys
were allowed to recover from the procedure for more than 1 mo.
They had previously been acclimatized to the chair restraint during
repeated training sessions several times a week for more than 1 mo
before the PET study began.
Drug Testing
FK960 was provided by Fujisawa Pharmaceutical Co., Ltd.
(Osaka, Japan), and was dissolved in sterile physiologic saline at a
concentration of 0.4 mg/mL before each study. 18F-FK960 (mean
radiochemical purity, 97.4%; mean specific activity, 954 GBq/mg)
was synthesized by an automated apparatus before each study, and
the product obtained from the apparatus was an 18F-FK960 solu-
tion in 2 mL of saline. Then, about 370 MBq of the 18F-FK960
solution was mixed with the solution of unlabeled FK960. With the
addition of saline, 0.1 mg of FK960 per kilogram of body weight,
containing about 370 MBq (mean  SD, 366  14 MBq) of
18F-FK960 solution (a final volume of 5 mL), was prepared.
PET Experiment
PET scans were obtained with a high-resolution animal PET
scanner (SHR-7700; Hamamatsu Photonics K.K., Hamamatsu,
Japan) with a transaxial resolution of 2.6 mm in full width at half
maximum in the center of the scan field and a center-to-center
distance of 3.6 mm (8). 68Ga–68Ge blank scanning (120 min) was
performed before each study. During catheterization of the femoral
artery for arterial blood sampling, each monkey was transiently
anesthetized with about 2% sevoflurane in a N2O:O2 gas mixture
(7:3). After catheterization, anesthesia was immediately discontin-
ued. For PET scans, each monkey’s head was fixed to a chair with
a head holder and was stereotactically aligned parallel to the
orbitomeatal plane with a laser marker; 68Ga–68Ge transmission
scanning (30 min) was then performed.
After the transmission scan, a probe was inserted from the
mouth to the stomach of each monkey. Through the probe, the 5
mL of prepared 18F-FK960 solution were administered, and an-
other 5 mL of saline were administered to wash the inside of the
probe. The remaining radioactivity in the probe was also measured
by a radioisotope calibrator (CRC-127R; Capintec Instruments
Inc., Ramsey, NJ) to calculate a net dose of 18F-FK960. Starting 5
min after oral administration of 18F-FK960, PET emission scan-
ning was performed for 4 h; the scan consisted of 48 frames of 5
min each. During emission scanning, each monkey’s ears were
unplugged, its eyes were open, and it was under a dimmed light.
Arterial blood samples were drawn (at 0, 10, 20, 30, 40, 50, 60,
80, and 100 min and at 2, 2.5, 3, 3.5, and 4 h) and were centrifuged
to obtain plasma. They were analyzed for radioactivity by a
-counter (1480 Wizard; Wallac Oy, Turku, Finland). Metabolites
were extracted by 0.5 mL of methanol from 0.5 mL of plasma, and
the extraction was performed twice on each sample. The methanol
extract fraction was concentrated into about 0.2 mL by a gentle
stream of nitrogen gas. Each 5 L of concentrated fraction was
spotted on a prelayered silica gel 60F254 thin-layer chromatography
plate (E. Merck AG, Darmstadt, Germany), of layer thickness 0.25
mm, alongside 5 L of methanol solution of authentic 18F-FK960.
The plate was eluted in an n-butanol, ethyl acetate, and water
(4:1:2) solvent system. After elution, the plate was dried and
placed in contact with a BAS1800 imaging plate (Fuji Photo Film
Co., Ltd., Tokyo, Japan). The imaging plate was read using a Fujix
BAS1800 bioimaging analyzer (Fuji Photo Film Co., Ltd.).
For each monkey, a region of interest was manually drawn on
a PET image of the entire brain (a slice of the orbitomeatal
plane  21.6 mm). The data obtained from plasma and PET, in
units of Bq/mL, were converted to units of mol/L according to
a calculated specific activity of 18F-FK960 preparation for each
study. All data were represented as mean  SE.
RESULTS
A typical PET image obtained from 30 to 90 min after
administration of an 18F-FK960 preparation is shown in
Figure 2. No marked focused accumulation was seen in the
brain; the distribution was likely according to blood flow
but was not distinctly so. The time–concentration curves for
the plasma and brain are shown in Figure 3 as mean  SE,
averaged over all subjects (n  3), at each point. No
metabolite was found in blood samples at any point. Max-
imal concentrations in the brain and plasma were 1.11 
0.30  107 mol/L (at 3.0  0.6 h after administration) and
4.04  1.29  107 mol/L (at 2.0  1.1 h after adminis-
tration), respectively. These mean maximal concentrations
were calculated from maximal concentrations determined in
each animal.
DISCUSSION
In this study, we used PET with 18F-FK960 to measure
the FK960 concentration after oral administration to con-
scious monkeys. PET can measure the radioactivity concen-
tration dynamically in a target organ in a living subject with
minimal invasion, and we expected that bridging data be-
tween animals and humans could be obtained using PET.
Therefore, we used nonhuman primates and studied them
while they were conscious and with the drug orally admin-
istered. After administration of FK960 at a dose of 0.1
mg/kg, the brain concentration became about 107 mol/L
3 h after oral administration. Ours may be the first report of
PET measurement of the brain concentration of a drug in
conscious monkeys.
Two prerequisites must be observed in applying PET for
pharmacokinetic studies of a new drug. First, one must be
FIGURE 1. Chemical structure of FK960 (N-(4-acetyl-1-
piperazinyl)-p-fluorobenzamide monohydrate). Asterisk denotes
position of 18F labeling.
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able to produce the exact molecular structure of the drug in
a positron-emitting form. It may be also desirable that the
positron-emitting nuclide not be easily eliminated in early
metabolism. Second, one must be able to correct for radio-
metabolites, which are detected quickly by imaging equip-
ment. FK960 has fluorine in the original structure, and the
metabolites could be determined by thin-layer chromatog-
raphy. FK960 is also metabolically stable enough within the
scanning period.
FK960 is an antidementia drug, and its mechanism of
action might be somatostatin activation (3). FK960 was
reported to enhance K-evoked release of somatostatin
from rat hippocampal slices (9). Somatostatin enhanced
LTP in the mossy fiber-CA3 pathway in intact guinea pig
hippocampal slices (4), and FK960 also enhanced LTP
through somatostatin activation (3). Somatostatin also en-
hanced the release of acetylcholine (10). Therefore, FK960
indirectly activates the release of acetylcholine and has
improving effects in animal models of scopolamine-induced
amnesia (1,2) and neuronal dysfunction (11).
FK960 has a bell-shaped dose–response relationship, and
the dose setting is still more a critical issue. However,
determining a clinical dose is difficult because species dif-
ferences usually exist between experimental animals and
humans. Species differences would be expected to be partly
due to differences in brain concentration as the result of
differences in absorption, distribution, metabolism, and per-
meability through the blood–brain barrier. The brain con-
centration could be measured even in humans with a method
similar to that of the present study. If any difference in brain
concentration between animals and humans were found, a
brain concentration would be expected to provide informa-
tion beneficial to the critical issue; that is, a large discrep-
ancy in brain concentration between animals and humans
might suggest a discrepancy in effective dose. In the case of
FIGURE 2. Typical PET images obtained
from 30 to 90 min after administration of
18F-FK960 preparation. Presented images
are 3.6-mm transverse slices, and slice 6
corresponds to orbitomeatal plane.
FIGURE 3. Time–concentration curves for plasma and brain
after peroral administration of FK960 (0.1 mg/kg) containing
18F-FK960 (366  14 MBq). Data are presented as mean  SE,
averaged over all subjects (n  3), at each point.
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FK960, 0.1 mg/kg was the dose at which FK960 could
reverse the cerebral blood flow response to somatosensory
stimulation abolished by scopolamine in conscious rhesus
monkeys (11). Furthermore, previous in vitro studies re-
vealed that FK960 enhanced K-evoked release of soma-
tostatin from rat hippocampal slices at more than 107
mol/L (9) and enhanced LTP in hippocampal slices with a
maximum augmentation at 107 mol/L (3). This concentra-
tion, 107 mol/L, agrees with the brain concentration at a
dose of 0.1 mg/kg in the present study. A further human
PET study is needed to confirm the brain concentration.
In the present study, no marked focused accumulation of
FK960 occurred in the brain. This result was not due to the
addition of unlabeled FK960 as a carrier. In our preliminary
study (data not shown), we examined whether intravenous
administration of a sufficient amount of unlabeled FK960 at 30
min after 18F-FK960 intravenous administration affected the
time course of 18F-FK960 itself, and we confirmed that dis-
placement did not occur in any brain regions. The mechanisms
by which FK960 enhances memory have been clarified; how-
ever, its target tissue in the brain still remains unclear.
CONCLUSION
We succeeded in using PET to measure the brain con-
centration of FK960 after oral administration to conscious
nonhuman primates. The measured value showed an en-
hancement of LTP in hippocampal slices that is expected to
have clinical efficacy. The method of this study is applicable
to human PET studies and would also facilitate applications
of PET to new drug development.
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